However, the silencing of IFN-α/β receptors 1 or 2 (IFNAR1 or IFNAR2), which constitute a loop to IFN-α signaling, causes a reduction in PD-L1 and MHC class I/II expression in glioma cells, as well as an enhanced susceptibility to immune cell lysis of NK cells. The gene discussed is IFNAR1; the disease is central nervous system cancer.